This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A third Look: Discussing the potential of 225Ac-PSMA I&T, a targeted alpha therapy being developed by Fusion Pharmaceuticals for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Ticker(s): FUSNWho's the expert?
- Radiation Oncologist with Intermountain Health
- Manages 50 patients with MCRPC
- Has prescribed Pluvicto to approximately 10 patients
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
